The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The pharmaceutical company reportedly opted to implement the cloud software provider's clinical trial management system to help streamline its processes.
Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.
The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.
The pharmaceutical company has announced 24 grants totaling nearly $8m USD to fuel training and support for community health workers and patient navigators.
A survey commissioned by Bristol Myers Squibb reveals healthcare providers are confident that immunotherapy can positively impact earlier-stage cancers.
The pharma firm is working with five US colleges and universities onto create programming designed to boost recruitment of Black talent in the industry
The two pharma firms will partner to study the efficacy of Opdivo, paired with a SHP2 inhibitor, to treat non-small cell lung cancer with KRAS mutations.
The two organizations have joined to create the Advocacy Exchange, a virtual platform designed to bring together patients, advocates and industry leader.
The therapeutic has been approved as an adjuvant treatment for varieties of esophageal cancers in patients who have received neoadjuvant chemoradiotherapy.
Celgene’s Inrebic becomes the first treatment for myelofibrosis to be approved by the US FDA since 2011 after having received a priority review and orphan drug designation.
The share price of BMS sank by over 7% after it stated that it would need to divest Celgene’s Otezla, a blockbuster treatment for psoriasis and psoriatic arthritis.
Bristol-Myers Squibb enters a multi-year strategic agreement with Concerto HealthAI to use machine learning to aid in protocol design for precision treatment and improved patient outcomes.
CRO stock prices fell initially following the news that Bristol-Myers Squibb was acquiring Celgene in a deal valued at $74bn. However, is 2019’s first mega-merger really a threat to service providers?
Bristol-Myers Squibb (BMS) has recruited IBM in its latest round of
outsourcing, granting the IT giant a $324m business process
outsourcing (BPO) contract.
Bristol-Myers Squibb (BMS) has announced its second collaboration
this year with a fellow big pharma firm, aimed once again at
reducing the inherent risk of drug development.
Bristol-Myers Squibb (BMS) has cut $400 million in annual expenses
over the last two years in order to boost its R&D pipeline and
achieve sales and earnings growth beginning in 2007.